-

Curant Health Appoints U.S. Market Leadership for Employer and Health Plan Markets

ATLANTA--(BUSINESS WIRE)--Curant Health, an organization that improves patient lives through proprietary Medication Care Management® products, announces the appointment of Beau Evans and Scott Harbin as U.S. Market Leads. In this executive role, Evans and Harbin will be responsible for leadership and oversight of U.S. Market Development for the Employer and Health Plan markets, respectively. Accomplished commercial healthcare executives, Evans and Harbin bring more than forty combined years of experience and expertise. Individually and collectively, they possess a proven track record of success as evidenced by numerous awards, including Vice President Cabinet, Circle of Excellence and Pinnacle Awards.

“Beau and Scott represent the ideal culmination of mindset and mission which are perfectly suited to developing, structuring and leading their respective markets in a manner which aligns Curant Health capabilities to partner and patient needs,” says Chief Revenue Officer Jake Caines. “Beau and Scott will lead the exponential business growth that we anticipate in the employer and health plan markets. This growth will come from the adoption of Curant Health Advisory, Engagement and Evidence Solutions powered by Products which are proven to impact partners in a measurable and meaningful way.”

For more than 20 years, Curant Health has specialized in delivering personalized healthcare driven by choice and defined by value. This is accomplished by innovative, longitudinal and relational patient engagement services delivered by dedicated clinicians and supported by proprietary platform and protocol technology. Curant Health is a fixture on the Atlanta Business Chronicle's Largest 50 Atlanta Private Companies list. Curant Health has received multiple Atlanta Business Chronicle Pacesetters Awards and ACG Fast 40 Awards for the fastest growing companies in Atlanta and the State of Georgia. Curant Health's proprietary Pharmacy Analytics platform MedPlan® was a Grand Finalist for Microsoft's 2013 Excellence Award for Innovation. Curant Health has been listed on the INC. 500/5000 seven times and recently recognized as “Best in Business 2021: Most Inspiring Companies of the Year.”

About Curant Health

Curant Health is a national outcomes-based patient support organization headquartered in the Atlanta area that delivers personalized healthcare driven by choice and defined by value. Curant Health collaborates with partners to deliver agreed upon and defined value which is validated to measurably improve patient and partner outcomes including reduced total cost of care, decreased emergency department and hospital utilization rates and improved patient Quality of Life (QoL). Curant Health’s patient-dedicated clinicians focus on transforming the patient journey by leveraging its proprietary omni-channel engagement platform and protocol which seamlessly delivers the appropriate level of intervention to the right patient at the right time with the right communication medium with the right frequency. Their balance of clinical and business intelligence expertise serves as the catalyst for bridging the chasm between Burden of Illness (BoI) and Return on Investment (RoI). For more information, visit www.curanthealth.com.

Learn More About Curant Health’s Employer and Health Plan Solutions

Curant Health Solutions for Employers and Health Plans are included but not limited to Products focused on Total Cost of Care Reduction, Productivity Improvement, High Cost & Complex Care Monitoring, Stars Adherence Improvement, HEDIS Gap Closure and Medication Reconciliation Post-Discharge. To learn more about any of these products, click the link below to set up an initial Discovery Dialogue meeting:

https://calendly.com/curanthealth/30-minute-intro

Contacts

Culver Lyons
Curant Health
clyons@curanthealth.com

Curant Health


Release Versions

Contacts

Culver Lyons
Curant Health
clyons@curanthealth.com

More News From Curant Health

Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products

ATLANTA--(BUSINESS WIRE)--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products. Rare disease therapies face unique challenges, including complex regulatory pathways and access barriers. This collaboration will leverage Cencora’s pharmaceutical logistics services and commercial...

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate the complexities of treatment. Patients will now benefit from Curant Rare’s proven high-touch care model, designed to ensure timely access to medication, address treatment barriers such as insurance and financial concerns, and...

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare is now the exclusive pharmacy partner for IWILFIN™, a groundbreaking therapy used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB). Beginning in August 2025, patients will transition to Curant Rare with one clear goal in mind: to ensure uninterrupted access to care while enhancing the patient and caregiver experience through the IWILFIN Cares® program. All patients will continue...
Back to Newsroom